Immatics N.V.
NASDAQ:IMTXBiotechnology
+$0.15 today
- Market cap
- $912.78M
- Beta
- 1.30
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$1.59
Volume 1.57M
Average 0.46M
IMTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Immatics N.V.NASDAQ: IMTX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 24.2% from a year ago
Cash & equivalents stood at €301.65M at the end of Q1 FY2026, up 24.2% from a year earlier and down 12.8% from the prior quarter. Over 3 fiscal years it compounded at +32.5% a year.
Context
- Cash & equivalents amounted to 55.5% of total assets at the end of Q1 FY2026, up 17.6 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +24.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
EUR · from the balance sheet
- Latest · FY2025
- 345.77M EUR
- Year-over-year change
- +46.1%
- 4-year CAGR
- +27.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 345.77M | +46.1% |
| FY2024 | 2024-12-31 | 236.75M | +8.4% |
| FY2023 | 2023-12-31 | 218.47M | +47.1% |
| FY2022 | 2022-12-31 | 148.52M | +11.7% |
| FY2021 | 2021-12-31 | 132.99M | — |
Cash & Equivalents vs competitors
How IMTX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +24.2% is the 3rd highest of 11, against a peer median of -20.7%.
- Cash & equivalents amounts to 55.5% of total assets for IMTX, versus a peer median of 34.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | €9.74B EUR | -5.2% | -17.9% | 47.9% | |
| Sep 2026 | $460.7M USD | +65.2% | +4.7% | 27.4% | |
| Mar 2026 | $452.68M USD | -5.1% | +5.1% | 42.2% | |
| Mar 2026 | €301.65M EUR | +24.2% | +32.5% | 55.5% | |
| Mar 2026 | $128.06M USD | -16.9% | +8.3% | 63.4% | |
| Mar 2026 | $99.37M USD | +28.7% | -16.4% | 69.1% | |
| Mar 2026 | $90.77M USD | -24.6% | -21.3% | 25.9% | |
| Mar 2026 | $51.83M USD | -29.7% | +0.6% | 5.0% | |
| Mar 2026 | $35M USD | -72.6% | -10.9% | 12.1% | |
| Mar 2026 | $30.31M USD | -28.6% | -5.8% | 7.7% | |
| Mar 2026 | $8.36M USD | -39.6% | -55.0% | 41.8% | |
| Peer median (excluding IMTX) | — | -20.7% | -8.4% | 34.6% | |
Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 132.99M | 148.52M | 218.47M | 236.75M | 345.77M |
| Short-term Investments | 12.12M | 213.69M | 207.42M | 367.7M | 123.37M |
| Net Receivables | 2.36M | 1.11M | 5.74M | 6.75M | 6.88M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 950K | 13.84M | 7.12M | 6.31M | 14.86M |
| Total Current Assets | 152.21M | 377.15M | 449.37M | 629.56M | 503.79M |
| Property, Plant & Equipment (Net) | 20.49M | 26.49M | 57.06M | 63.71M | 54.87M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.32M | 1.63M | 1.52M | 1.63M | 1.58M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 636K | 2.55M | 2.02M | 1.25M | 1.85M |
| Total Non-current Assets | 22.44M | 30.67M | 60.6M | 66.59M | 58.3M |
| Total Assets | 174.65M | 407.82M | 509.97M | 696.15M | 562.1M |
| Account Payables | 3.01M | 4.03M | 7.67M | 10.11M | 339.86K |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.76M |
| Tax Payables | 1.76M | 7.72M | 7.86M | 3.77M | 0 |
| Deferred Revenue | 50.4M | 64.96M | 100.4M | 35.91M | 15.81M |
| Other Current Liabilities | 28.04M | 17.88M | 20.48M | 4.77M | 2.81M |
| Total Current Liabilities | 95.15M | 106.45M | 156.55M | 67.99M | 42.99M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 5.8M | 3.81M |
| Deferred Revenue (Non-current) | 48.23M | 75.76M | 115.53M | 34.16M | 18.53M |
| Other Non-current Liabilities | 68K | 42K | 115.53M | 0 | 0 |
| Total Non-current Liabilities | 55.44M | 88.2M | 128.33M | 53.32M | 35.21M |
| Total Liabilities | 150.58M | 194.66M | 284.88M | 121.3M | 78.2M |
| Common Stock | 629K | 767K | 847K | 1.22M | 1.34M |
| Retained Earnings | (537.81M) | (500.3M) | (597.29M) | (589.54M) | (785.65M) |
| Accumulated OCI | (3.95M) | (1.48M) | (1.64M) | 1.03M | (8.59M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 24.06M | 213.16M | 225.08M | 574.84M | 483.89M |
| Total Debt | 9.85M | 14.56M | 15.4M | 16.2M | 15.63M |
| Net Debt | (123.14M) | (133.96M) | (203.07M) | (220.55M) | (330.14M) |
Immatics N.V.
NASDAQ:IMTX
Intrinsic Alpha fair value
Locked
Current Price
$6.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.